Survival Boost With Oncolytic Virus Combo in Glioblastoma Subset
(MedPage Today) -- The combination of oncolytic DNX-2401 virotherapy with pembrolizumab (Keytruda) failed to meet a phase I/II study's primary endpoint of objective response rate (ORR) in patients with recurrent glioblastoma, but did demonstrate... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 17, 2023 Category: Hematology Source Type: news

Oncolytic Virus-Driven Immune Modulation and Therapeutic Combinations:...
This webinar will provide a short introduction to immuno-oncology, the shortcomings of current standard of care, checkpoint inhibitors and the mechanism of action of oncolytic virotherapies.(PRWeb October 17, 2019)Read the full story at (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 17, 2019 Category: Pharmaceuticals Source Type: news

Combo of virotherapy and radiotherapy shows early promise in patients with esophageal cancer
(American Association for Cancer Research) The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

Science Saturday: Bitten by the virotherapy bug
Every day more than 1,600 Americans die from cancer. Most?of them have cancer that can't be cured with traditional?methods -- surgery, radiation and chemotherapy. The father?of?Evanthia Galanis, M.D., was one of them. He died in the late 1990s from?melanoma?when his daughter was?a junior faculty member at?Mayo Clinic. "My father would have better treatment options today," [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - February 16, 2019 Category: Research Source Type: news

Hop to it: Researchers evaluate rabbits' evolved resistance to myxoma virus
(Arizona State University) Partnering with the University of Cambridge and several other research institutes, Biodesign researchers, as part of Grant McFadden's Center of for Immunotherapy, Vaccines and Virotherapy, validated the role of specific rabbit genes in contributing to this acquired resistance in research published in Science Magazine. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 14, 2019 Category: Biology Source Type: news

The Emerging Role of Oncolytic Virus Therapy Against Cancer The Emerging Role of Oncolytic Virus Therapy Against Cancer
Review the latest on oncolytic virotherapy and viruses currently in clinical testing.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Ludwig Cancer Research and Cancer Research Institute launch cancer clinical trial
(Ludwig Institute for Cancer Research) Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI ® (durvalumab) for advanced ovarian and colorectal cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2018 Category: International Medicine & Public Health Source Type: news

German research advances in cancer and blood disorders reported in human gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) Virotherapy capable of destroying tumor cells and activating anti-tumor immune reactions, and the use of engineered hematopoietic stem cells (HSCs) to deliver replacement genes that have the potential to cure blood diseases are among the key areas of gene therapy being advanced by German researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

Oncolytic virotherapy offers new approach in treating brain tumors
For Jennifer Amsley and daughter Xia Martinez of Maryland, an oncolytic virotherapy study at Children ’s of Alabama has strengthened their resolve to fight and their desire for a sense of normalcy. Xia, 14, has an aggressive glioma brain tumor and an MRI showed new growth. That’s when doctors in Maryland informed Xia and her family of a clinical trial conducted by Dr. Gregory Friedman, associat e professor of pediatrics at the University of Alabama at Birmingham (UAB) and Children’s, and scientist… (Source: Health Care:Biotechnology headlines)
Source: Health Care:Biotechnology headlines - September 1, 2017 Category: Biotechnology Authors: Content provided by Children ’s of Alabama Source Type: news

Paclitaxel and MG1 Oncolytic Virus for Breast Cancer Paclitaxel and MG1 Oncolytic Virus for Breast Cancer
Are paclitaxel and oncolytic virotherapy synergistic and compatible for breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Using Viruses to Boost Mesothelioma Immunotherapy
Immunotherapy through clinical trials is becoming a promising treatment option for some mesothelioma patients. Checkpoint inhibitor drugs, such as Keytruda, already have U.S. Food and Drug Administration (FDA) approval as first-line treatments for non-small cell lung cancer (NSCLC), edging immunotherapy drugs closer to becoming a viable second-line therapy for other thoracic cancers, including pleural mesothelioma. However, overall response to immune therapies remains relatively low. Researchers across the country are striving to enhance responsiveness to immunotherapy drugs. Leading that trend is viroimmunotherapy, or t...
Source: Asbestos and Mesothelioma News - June 6, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Biomedicines checkpoint blockade Checkpoint inhibitor drugs clinical trials for mesothelioma Dr. Alexander Dash Dr. Manish Patel FDA approval Keytruda immune response cancer immunotherapy response mesothelioma intratumoral injections k Source Type: news

EC awards grant to commercialise Latima ’s cancer virotherapy medicine
The European Commission (EC) has awarded a grant to Latima to commercialise its cancer virotherapy medicine in the European Union (EU) markets. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 21, 2016 Category: Pharmaceuticals Source Type: news

PsiOxus begins ovarian cancer trial of paclitaxel with oncolytic virus enadenotucirev
UK-based PsiOxus Therapeutics (PsiOxus) has started its Octave trial of paclitaxel combined with the oncolytic virotherapy enadenotucirev to treat patients with ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - March 11, 2016 Category: Pharmaceuticals Source Type: news

Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring
Herein we describe the use of the vaccinia virus strain GLV-1h68 as a theragnostic agent in cancer models. To date, GLV-1h68 has been used successfully in more than 50 xenograft tumor models. The recombinant vaccinia virus strain has been equipped with heterologous expression cassettes for a luciferase-fluorescent protein fusion gene, bacterial beta-galactosidase, as well as a bacterial glucuronidase. (Source: Springer protocols feed by Cancer Research)
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news

Virotherapy: skin cancer successfully treated with herpes-based drug
‘Virotherapy’ uses modified herpes virus to attack melanoma cells and has potential to overcome cancer even when disease has spread throughout the bodyPatients with aggressive skin cancer have been treated successfully using a drug based on the herpes virus, in a trial that could pave the way for a new generation of cancer treatments.The findings mark the first positive phase 3 trial results for cancer “virotherapy”, where one disease is harnessed and used to attack another. If approved, the drug, called T-VEC, could be more widely available for cancer patients by next year, scientists predicted. Continue reading.....
Source: Guardian Unlimited Science - May 27, 2015 Category: Science Authors: Hannah Devlin Science correspondent Tags: Science Medical research Cancer Skin cancer Immunology Biochemistry and molecular biology Health UK news Source Type: news